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Abstract
The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major 
determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence 
from both laboratory and clinical studies to suggest that in addition to inhibiting platelet aggregation, antithrombotic medi-
cations have shear-dependent effects, potentiating thrombus fragility and/or enhancing endogenous fibrinolysis. Such shear-
dependent effects, potentiating the fragility of the growing thrombus and/or enhancing endogenous thrombolytic activity, 
likely contribute to the clinical effectiveness of such medications. It is not clear how much these effects relate to the measured 
inhibition of platelet aggregation in response to specific agonists. These effects are observable only with techniques that 
subject the growing thrombus to arterial flow and shear conditions. The effects of antithrombotic medications on thrombus 
stability and ways of assessing this are reviewed herein, and it is proposed that thrombus stability could become a new target 
for pharmacological intervention.
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Introduction
Platelet aggregation plays a central role in the development 
of arterial thrombotic events such as myocardial infarction, 
ischaemic stroke and peripheral arterial thrombosis [1]. 
Antiplatelet medications such as aspirin and  P2Y12 inhibi-
tors, which inhibit platelet aggregation, are established as 
the cornerstone treatment for preventing such thrombotic 
events [2].
It is generally accepted that antiplatelet agents exert their 
antithrombotic effects by inhibiting agonist-induced platelet 
aggregation. It is for this reason that point-of-care platelet 
function tests that assess platelet aggregation in response 
to specific agonists, such as arachidonic acid, adenosine 
diphosphate and thrombin receptor activating peptide have 
been developed. However, in stenosed arteries, it is a shear 
gradient-dependent platelet aggregation mechanism which 
drives thrombus formation, while soluble agonists have only 
secondary roles, mainly stabilizing the formed aggregate [3].
Further, some important determinants of thrombus for-
mation, such as thrombin generation, fibrinolytic activity 
and endothelial dysfunction in patients on dual antiplatelet 
therapy are not determined by platelet aggregability [4]. For 
example, plasminogen activator inhibitor (PAI-1), a major 
determinant of fibrinolysis resistance, is released from cir-
culating platelets following platelet activation [5] and yet 
platelet aggregation is not associated with PAI-1 release [4].
This finding together with the recognition that some 
patients continue to experience recurrent thrombotic events 
despite dual antiplatelet medications, has led to the proposal 
that some patients may benefit from anticoagulant treatment 
following percutaneous coronary intervention [6].
Amongst patients receiving dual antithrombotic 
therapy, some patients despite compliance exhibit high 
on-treatment platelet reactivity (so called “antiplatelet 
resistance”) and it was shown that this was predictive of 
recurrent ischaemic events [7, 8]. However, modulation 
of such high on-treatment platelet reactivity with admin-
istration of more potent but still very specific inhibitors 
of agonist-induced platelet aggregation, failed to translate 
into a reduction in ischaemic events. Thus on-treatment 
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platelet hyper-reactivity therefore cannot be considered 
as a risk factor requiring intervention for secondary pre-
vention after percutaneous coronary revascularization [4, 
8] and routine platelet function testing to detect high on-
treatment platelet reactivity is not advocated [9].
There is however, evidence to suggest that antiplatelet 
agents may have additional benefits, in addition to inhibi-
tion of platelet aggregation, which may impact on throm-
bus stability.
The stability of an arterial thrombus is the major deter-
minant of the severity and extent of distal tissue damage in 
myocardial infarction and ischaemic stroke [10]. Throm-
bus that is unstable is susceptible to fibrinolysis, leading 
to disruption of the adhesive bonds within the thrombus 
mass. This, combined with the effects of flow, result in dis-
lodgement or downstream embolization of the thrombus, 
in whole or in part. On the other hand, a stable thrombus, 
able to resist fibrinolysis and high arterial back-pressure, 
will result in potential lasting vessel occlusion with pro-
portionately more extensive tissue damage. The stability 
of the thrombus, and its ability to withstand dislodgement 
by high arterial flow, is determined by the combination of 
the strength of the attachment of the thrombus to the ves-
sel wall, the firmness and the density of the tightly-packed 
platelet core of the thrombus, and the structure and density 
of the fibrin network (Fig. 1).
It has been observed that shear-induced platelet aggrega-
tion is inversely proportional to shear rate. Shear-induced 
platelet aggregation occurs when shear-activated platelets 
aggregate. The intensity of shear rate can regulate both the 
capture of flowing platelets into the aggregates and the size 
of those aggregates. Aggregation is less likely to occur at 
high shear stress sites because hydrodynamic forces carry 
platelets away with the flow, and aggregation appears to 
occur predominantly just downstream to this, at location(s) 
where shear drops but where platelets are able to aggregate 
via von Willebrand Factor (vWF). Any model involving only 
the effect of aggregation would inevitably yield to a steady 
state where all platelets are clumped together in a single 
aggregate. Hellmuth et al. developed a mathematical kinetic 
model to better understand the mechanisms of shear-induced 
platelet aggregation [11]. Previous mathematical models had 
considered hydrodynamic effects inhibiting platelet aggrega-
tion by dislodgement, and incorporated this into models of 
aggregation efficiency. However, Hellmuth et al. postulated 
that this alone was too simplistic, since a realistic theoreti-
cal steady state can only occur when two opposite forces 
come to equilibrium. Their model, incorporating not only 
Fig. 1  Influences determining arterial thrombus stability, under high 
shear conditions. The strength of the attachment to the vessel wall 
and the tightness of the platelet core determine its ability to resist dis-
ruption by high shear forces and fibrinolysis. Medications that impact 
on thrombus stability are shown on left, NOAC non vitamin K oral 
anticoagulant
595Potentiation of thrombus instability: a contributory mechanism to the effectiveness of…
1 3
aggregation, but also disaggregation and breakup processes, 
implies that aggregates are less noticed at higher shear rates 
because they break apart very quickly, instead of building 
up at a slower pace. This mathematical modeling appears to 
be supported by clinical findings.
Substantial laboratory and clinical data suggest that cur-
rent antiplatelet and antithrombotic medications exert some 
of their important effects by potentiating thrombus insta-
bility and susceptibility to fibrinolysis (Table 1). The aim 
of this review is to discuss evidence supporting the asser-
tion that current antithrombotic medications variably, but 
significantly, reduce thrombus stability and that this in part 
contributes to their therapeutic effect.
Mechanism of thrombus formation at high 
shear
High shear rate at the arterial wall results in endothelial 
expression of vWF which results in platelet adhesion via 
interaction of platelet glycoprotein Ib-IX-V with vWF, with 
a supporting role for the P-selectin/P-selectin glycoprotein 
ligand 1 axis. This is followed by firm platelet adhesion 
to the endothelium via interaction of platelet aIIbb3 with 
endothelial avb3 and intercellular adhesion molecule 1. 
Subsequently, thrombin, the thrombospondin-1/CD36 axis 
and cyclooxygenase 1 all play a role in subsequent platelet 
activation and thrombus stabilization [12].
Platelet receptors and ligands involved in initial integ-
rin aIIbb3 activation and reversible platelet aggregation are 
shown in Fig. 2 [13]. As a result of activation, several ligand/
receptor pairs and adhesion proteins are expressed on the 
platelet surface, that form interactions across platelet–plate-
let contacts thus forming a tightly packed platelet core in the 
growing thrombus [14].
Contact-dependent signaling mechanisms are implicated 
in platelet contraction, irreversible platelet aggregation and 
stabilization of platelet aggregates. Subsequent activation of 
platelets is further promoted by degranulation and release of 
adenosine diphosphate (ADP) and thromboxane. Degranu-
lation also results in release of CyPA, a potent stimulant of 
platelet activation which also enhances binding of fibrinogen 
to platelets [15]. Thrombin activates platelets and cleaves 
fibrinogen into fibrin, promoting thrombus growth and sta-
bilization. Fibrin formed by the coagulation process further 
stabilizes the platelet aggregate. Plasma coagulation factors, 
via the intrinsic (factor XII, FXII) and extrinsic (tissue fac-
tor) pathways, mediating platelet-dependent thrombin and 
fibrin generation, stabilize the growing thrombus. Thrombin 
also suppresses its own generation by binding to endothelial-
expressed thrombomodulin. Thrombomodulin-bound throm-
bin activates protein C, which inactivates coagulation factors 
Va and VIIIa leading to dampening of thrombin generation. 
The coagulation cascade plays an important role in thrombus 
formation and stabilization, primarily via thrombin, and sec-
ondary feedback loops, among others via thrombospondin-1.
Impact of antithrombotic medications 
on thrombus stability
Aspirin
Although the cardioprotective effects of aspirin are well 
recognized, after more than three decades of research, the 
mechanism of aspirin’s antithrombotic effect is still not fully 
understood. The prevailing view is that aspirin impairs plate-
let aggregation and subsequent thrombus formation via inhi-
bition of platelet thromboxane synthesis.
However, experimental evidence indicates a significant 
mismatch between the potent inhibitory effect of aspirin 
on platelet aggregation measured in vitro in anticoagu-
lated blood, under static conditions, and the magnitude of 
the effect measured in vivo, under pathologically-relevant 
flow conditions. This discrepancy suggests that aspirin’s 
antithrombotic effect may involve other mechanisms of 
action, in addition to the inhibition of cyclooxygenase.
In a perfusion chamber set-up, aspirin significantly 
reduced thrombus volume and thrombus height in the pres-
ence of citrate but no significant effects were observed in 
native, non-citrated blood [16–19]. Furthermore, aspirin has 
been shown to reduce platelet activation only under con-
ditions of low shear stress, with minimal effects at higher 
shear stress or under dynamic flow conditions [20]. Aspirin’s 
Table 1  Effect of various 
anti-thrombotic drugs on the 
main determinants of thrombus 
stability
GPI glycoprotein IIb/IIIa inhibitors, NOAC non-vitamin K oral anticoagulant
DRUGS Fragility of plate-
let core
Retraction of 
thrombus
Fibrin structure/
fibrinolysis
Non-adherence 
to endothelium
Aspirin + + +
P2Y12 antagonists + +
GPI + + +
NOAC + +
Factor XI inhibitors + + +
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antithrombotic effect was lost at a pathologically-relevant 
arterial shear rate of 10,500 s−1, and loss of antiplatelet 
effect at high arterial shear rates has also been demonstrated 
in patients with severe atherosclerotic stenoses [21]. Perfu-
sion of aspirin-treated blood over endothelium-denuded rab-
bit aorta in an annular perfusion chamber did not reduce the 
number of adherent platelets or the subsequent aggregation 
(thrombus volume) relative to control blood, but the most 
striking effect of aspirin was the virtual absence of platelet 
thrombi at the end of perfusion, indicating that aspirin may 
act by increasing thrombus fragility [22].
It was shown that aspirin directly stimulated the activity 
of endothelial nitric oxide (NO) synthase and increased 
bioavailability of systemic NO [23]. The addition of aspi-
rin to blood perfused at high shear rate markedly increased 
the release of NO from the endothelium into the circula-
tion. This effect was specific to aspirin and not induced by 
other nonsteroidal anti-inflammatory drugs or by selec-
tive cyclo-oxygenase inhibitors. In addition to inhibiting 
Fig. 2  Key platelet and plasma 
proteins contributing to throm-
bus stability. I Platelet receptors 
and ligands involved in initial 
integrina IIbb3 activation and 
reversible platelet aggregation. 
The absence of these molecules 
increases thrombus instability. 
Also indicated is a box with 
intracellular signalling proteins 
controlling this process. II 
Contact-dependent signalling 
mechanisms implicated in 
platelet contraction and irrevers-
ible platelet aggregation. Fibrin 
formed by the coagulation 
process stabilizes the platelet 
aggregate. III Plasma coagula-
tion factors, via the intrinsic 
(factor XII, FXII) and extrinsic 
(tissue factor, TF) pathways, 
mediating platelet-dependent 
thrombin and fibrin generation, 
stabilizing a growing thrombus. 
Also indicated is a primary 
mechanism of platelet-leucocyte 
interaction via P-selectin and 
PSGL-1. Reproduced with 
permission from Cosemans 
et al. [14]
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the adherence of platelets to endothelium and subsequent 
platelet aggregation, NO also inhibits the contractile 
mechanism in platelets. Contraction of platelets results in 
the formation of a tightly packed platelet aggregate, which 
imparts stability to the thrombus and resistance to fibrinol-
ysis [10], and such “clot retraction” makes an important 
contribution to thrombus stability. By inhibiting the plate-
let contractile mechanism, NO attenuates “clot retraction”, 
resulting in reduced stability and micro-embolization of 
the developing arterial thrombus. In a microfluidic throm-
bosis model, at high shear rates, aspirin, even at maximum 
doses of twenty times the recommended daily oral dose, 
was unable to fully prevent occlusive thrombosis. In con-
trast, the odds of detachment or embolization were almost 
five times higher when a sample was treated with aspirin 
compared to that without aspirin [24].
Using a perfusion chamber to observe the growth and 
fragmentation of thrombus, it was shown that whilst aspi-
rin or clopidogrel, either alone or in combination, failed to 
reduce thrombus growth in some individuals; in combina-
tion, caused marked destabilization of the formed occlusive 
thrombus in all subjects [25]. These observations are sup-
ported by the finding that aspirin directly alters clot struc-
ture, resulting in the formation of clots with thicker fibrin 
fibres and bigger pores, which are easier to lysis [26, 27].
These laboratory findings, suggesting a mismatch 
between aspirin’s anti-aggregatory effects and its effects 
under high shear conditions in native blood, have also been 
supported by the findings of some recent clinical studies. 
Although it was postulated that patients with high on-
treatment platelet reactivity (HTPR) despite taking aspirin 
would have a higher risk of adverse cardiovascular events, 
this postulate has been challenged. A recent study investi-
gating the association between cardiovascular events and 
the most common laboratory indices of aspirin’s antithrom-
botic effects, namely HTPR and residual cyclo-oxygenase 
(COX)-1 activity, found that neither HTPR nor high residual 
COX-1 activity was significantly associated with likelihood 
of cardiovascular events [28]. The largest such study so far 
undertaken, in which platelet aggregation was measured 
in 900 high-risk patients with stable coronary artery dis-
ease taking aspirin as their sole antithrombotic medication, 
showed that neither HTPR nor thromboxane  B2 levels were 
predictive of cardiovascular events over a 3-year follow-up 
[29].
P2Y12 receptor antagonists
Evidence suggests that there may be two distinct phases 
in the stabilization of a growing thrombus. The rapid first 
phase involves the tightening of platelet–platelet contacts 
in the loose platelet aggregate, resulting in a tight platelet 
core of thrombus with little space between platelets. Platelet 
activation during thrombus formation is localized to this 
central core, surrounded by a shell of non-activated platelets. 
The second, slower phase is linked to thrombin generation 
and fibrin formation.
Adenosine diphosphate plays an important role in the 
formation of a tightly packed, firm platelet core and thus 
in the maintenance of thrombus stability [30]. The  P2Y12 
receptor is required for sustained activation of integrin 
αIIbβ3, irreversible platelet aggregation and thrombus sta-
bilization [31]. The important role of continuous signalling 
by the ADP autocrine loop in the maintenance of thrombus 
stability, acting through the  P2Y12 receptor, was confirmed 
using an ex vivo perfusion chamber technique. Whilst  P2Y12 
receptor antagonist treatment variably reduced the rate of 
thrombus growth, it consistently reduced thrombus stabil-
ity and induced thrombus fragmentation [32]. In an in vivo 
mesenteric artery injury model in  P2Y12 -null mice, only 
small unstable thrombi formed which did not reach occlusive 
size [33].
Electron microscopy revealed that in response to ex vivo 
ADP stimulation, blood from patients taking clopidogrel 
formed loosely packed, unstable thrombi, compared to blood 
from untreated patients, indicating that clopidogrel impaired 
the formation of the platelet-to-platelet contacts needed for 
normal thrombus growth and stabilization [34].
In addition to inhibiting peak platelet aggregation in 
response to ADP,  P2Y12 antagonists have been shown to 
greatly enhance subsequent disaggregation through desta-
bilisation of platelet–platelet contacts, and it has been pro-
posed that measurement of disaggregation may be superior 
to measures of peak aggregation as a way of identifying 
 P2Y12 inhibitor non-responsiveness and may allow tailoring 
of pharmacotherapy [35–37]. In patients on dual antiplatelet 
therapy comprising aspirin and a  P2Y12 inhibitor, disaggre-
gation following specific agonist-induced platelet aggrega-
tion was variably but significantly increased [38].
Clopidogrel was shown to improve endothelial function 
and systemic NO bioavailability in patients with coronary 
artery disease [39]. In contrast to aspirin, this effect appeared 
to be related to  P2Y12 receptor inhibition. As described for 
aspirin, increased synthesis and release of NO from the 
endothelium affects thrombus stability by weakening the 
attachment of the thrombus to the vessel wall and by inhib-
iting clot retraction, leading to enhanced thrombus fragility. 
Furthermore, thrombus de-stabilisation may be responsible 
for the benefits of clopidogrel in the setting of therapeutic 
fibrinolysis. Addition of clopidogrel to aspirin and fibrino-
lytic therapy in patients with ST-segment elevation myo-
cardial infarction was shown to significantly improve the 
patency rate of the infarct-related artery and reduced the 
frequency of ischaemic complications compared to aspirin 
and fibrinolysis alone [40, 41]. In a model of carotid injury, 
intravital fluorescence microscopy showed that thrombus 
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formation was markedly unstable in the presence of  P2Y12 
inhibition with ticagrelor or cangrelor. The  P2Y12-dependent 
thrombus stabilization was accompanied by increased fibrin 
binding, and this  P2Y12 function was restricted to high shear 
flow conditions [42]. Freshly formed in vitro platelet aggre-
gates were more rapidly dispersed by ticagrelor than control 
as assessed by light transmission aggregometry and micros-
copy indicating that signaling via  P2Y12 may be critical for 
early platelet thrombus stabilization [43]. An in vivo murine 
arterial thrombosis model showed that early thrombotic 
occlusion was partially reversed by intravenous adminis-
tration of ticagrelor with increased flow and reduction in 
thrombus size, implying that  P2Y12 antagonism disrupts the 
stability of newly formed platelet aggregates, promoting dis-
aggregation [43].
Glycoprotein IIb/IIIa inhibitors
In addition to the well-recognised effects of glycoprotein 
IIb/IIIa inhibitors (GPI) in preventing platelet aggregation, 
GPI can also promote instability of pre-formed thrombi by 
enhancing platelet disaggregation, reducing clot retraction, 
and reducing soluble CD40 ligand release from platelets 
[44]. Abciximab, when added after ADP-induced platelet 
aggregation in vitro, dose-dependently enhanced platelet 
thrombus disaggregation and could disperse the platelet 
aggregates down to individual platelets [45], leading to 
increased fibrin exposure, clot permeability and suscepti-
bility to fibrinolysis [46].
Observation of the three dimensional structure of platelet 
thrombi formed on a collagen surface, showed that perfusion 
of blood containing the glycoprotein inhibitors abciximab, 
eptifibatide, or tirofiban over the formed thrombus resulted 
in thrombus dissolution, whereas this was not seen with con-
trol blood [32, 47]. Such addition of GPI to whole blood 
under dynamic flow conditions reduced platelet thrombus 
volume by > 75%, mainly through potentiation of frequent 
embolization.
Observations from capillary perfusion systems and plate-
let aggregometry studies showed that abciximab and eptifi-
batide readily dispersed freshly-formed platelet aggregates, 
an effect mediated through dissociation of fibrinogen from 
the platelet surface [48]. Others have suggested that eptifiba-
tide in combination with another antiplatelet agent, but not 
alone, could enhance thrombus disaggregation [32].
Non‑vitamin K oral anticoagulants (NOACs)
Thrombin, the most potent agonist of platelet aggregation, 
determines the formation of fibrin and physical characteris-
tics, inhibits fibrinolysis and plays a central role in throm-
bus growth and stability [49]. Despite the commonality of 
inhibiting thrombin generation, there would appear to exist 
important differences between the various non-vitamin K 
oral anticoagulants (NOACs) in their impact on thrombo-
genesis and fibrinolysis [50]. The direct thrombin inhibitor 
dabigatran decreased thrombus stability in a murine model 
of venous thrombosis through a FXIII-dependent effect [51] 
and was also shown to enhance the susceptibility of in vitro 
plasma clots to t-PA-induced lysis, as detected by a turbi-
dometric assay, that was mediated through TAFI activation 
[52, 53]. This reduction in thrombus stability was not seen 
with indirect thrombin inhibitors (rivaroxaban and apixa-
ban) when assessed with a turbidometric assay of clot lysis 
[37]. However, a very recent publication showed that addi-
tion of rivaroxaban in vitro enhanced urokinase plasminogen 
activator activity resulting in enhanced fibrinolytic effects 
[54]. Urokinase plasminogen activator is a serine protease 
for plasminogen, the inactive form of plasmin. Activation 
of plasmin triggers a proteolysis cascade that participates 
in thrombolysis by increasing fibrinolysis. Using an ex vivo 
test of thrombosis and thrombolysis, where flowing blood 
is subjected to high shear, apixaban, rivaroxaban and dabi-
gatran all exhibited a trend toward enhancing endogenous 
thrombolytic status [55].
Novel antithrombotic drugs that may impact 
on thrombus stability
Real-time visualization of thrombus formation in experi-
mental studies has shown that reducing the propagation 
of the thrombus and reducing its stability may be a novel 
way of reducing thrombosis. Not surprisingly, a number 
of novel antithrombotic agents have been developed and 
hold promise in reducing thrombus stability, discussed in a 
recent review in detail [56]. These can be broadly grouped 
into antiplatelet and anticoagulant strategies, and some of 
those agents that may be particularly effective at altering 
thrombus stability are discussed below.
Anticoagulants
Studies using animal models of thrombosis revealed that 
the contact activation plays an important role in thrombus 
formation while it has little or no role in haemostasis.
Factor XI inhibition
Under pathologically-relevant shear conditions, factor 
XI has been shown to enhance coagulation, adhesion and 
aggregation of platelets and thrombus growth on colla-
gen or tissue factor coated surfaces. Factor XI also pro-
tected the clot/thrombus against lysis once it was formed 
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[57–59]. In contrast to wild-type mice, mice deficient in 
factor XI (FXI) failed to form thrombus in a ferric chlo-
ride-induced vena cava thrombosis model and exhibited 
enhanced clot lysis [60]. In animal models of thrombo-
sis, inhibition of FXI enhanced thrombolysis, prevented 
or reduced thrombus formation and growth, and rendered 
the thrombus formed more unstable and easily fragmented 
[32, 61]. In a mouse carotid injury model, treatment with 
FXI antisense oligonucleotides did not impair initial plate-
let adhesion and platelet plug formation, but significantly 
attenuated subsequent thrombus formation and fibrin 
deposition, with formed thrombi that were much more 
unstable than thrombi from placebo-treated cohorts [61]. 
The first FXI-specific strategy to be tested in humans was 
the subcutaneously-administered FXI-directed antisense 
oligonucleotide IONIS-416858. In a phase 2 study of 300 
patients undergoing elective knee arthroplasty, IONIS-
416858 reduced the occurrence of venous thromboembo-
lism and also reduced bleeding compared to enoxaparin 
[61]. Antisense oligonucleotide, aptamers, antibodies, 
and small molecules provide a growing armamentarium 
of agents to reduce thrombosis without increasing bleed-
ing [62].
Factor XII inhibition
Inhibition of activated Factor XII (FXIIa) provides throm-
boprotection by reducing clot firmness [63]. As revealed by 
intravital microscopy, Thrombi created in injured mesenteric 
vessels of FXII-deficient mice were unstable and prone to 
embolization [64]. A recombinant fully human FXIIa activ-
ity neutralizing antibody (3F7) has shown promise in animal 
studies. It has been shown to dose-dependently reduce total 
and peak thrombin formation [65]. Under flow conditions, 
3F7 dose-dependently reduced thrombus formation on col-
lagen and almost completely (< 5% surface covered) abol-
ished thrombus formation at arterial shear rates in a carotid 
injury model. In an extracorporeal membrane oxygenation 
cardiopulmonary bypass system in rabbits, 3F7 prevented 
thrombosis as just as effectively as heparin, but in contrast 
to heparin, did not did not increase bleeding [65].
Antiplatelet agents
There are currently no inhibitors in routine clinical use tar-
geting the primary platelet receptors, glycoprotein Ibα or 
glycoprotein VI, or their ligands (vWF/collagen) that initiate 
platelet adhesion and activation and become increasingly 
important as the shear rate increases.
Platelet glycoprotein VI inhibition
Inhibition of glycoprotein VI-dependent pathways by inter-
fering in vascular collagen sites could reduce thrombosis in 
the setting of atherosclerotic plaque rupture, such as in myo-
cardial infarction. Revacept, a soluble dimeric glycoprotein 
VI-Fc fusion protein has been shown to reduce platelet adhe-
sion by blocking vascular collagen in plaques or erosion and 
to be safe in preclinical studies. A phase I study in humans 
showed that Revacept dose-dependently inhibited collagen-
induced platelet aggregation without a significant effect 
on bleeding time. In contrast, ADP- or thrombin receptor 
activating peptide-dependent platelet aggregation remained 
unaltered [66].
Selective inhibition of platelet inhibition integrin αIIbβ3
Antagonists of the platelet integrin αIIbβ3 are potent anti-
thrombotic drugs, but also have the life-threatening adverse 
effect of bleeding. Integrins transmit signals bidirectionally 
and outside-in signalling greatly potentiates thrombosis. An 
inhibitor of Gα13-integrin interaction selectively abolishes 
outside-in signalling, leading to suppression of thrombosis 
without affecting bleeding time [31].
Inhibition of CyPA
Platelet degranulation results in release of CyPA, a potent 
stimulant of platelet activation which also enhances binding 
of fibrinogen to platelets. Inhibition of extracellular CyPA 
by specific inhibitors, such as MM284 or specific antibody-
based antagonists, may modulate thrombus propagation 
without affecting the haemostasis [15].
Discussion
Whilst the generally accepted view is that antiplatelet 
agents exert their antithrombotic effects by inhibiting plate-
let aggregation, there is ample data from both laboratory 
and clinical studies to suggest that in addition to inhibiting 
platelet aggregation, antithrombotic medications in current 
use increase thrombus fragility and/or enhance endogenous 
fibrinolysis. Such interference with the mechanisms that 
normally impart stability to an arterial thrombus and enable 
it to resist high shear rates, likely contributes to the thera-
peutic effect of antithrombotic medications. It is not clear 
how much these effects relate to the measured inhibition of 
platelet aggregation in response to specific agonists. Most 
tests of platelet reactivity in clinical use are performed on 
anticoagulated blood under static conditions or at flow rates 
that are too low to be pathologically relevant, and there-
fore cannot assess thrombus stability. This is at least in part 
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why these pharmacological effects of such medications have 
been relatively overlooked, in comparison to the effects on 
platelet inhibition, which have been extensively studied. The 
assessment of the impact of pharmacotherapies on thrombus 
stability necessitates that the in vitro thrombus be subjected 
to pathologically-relevant flow and shear conditions. There 
is now a need for such clinically applicable testing of throm-
bus stability in individual patients to assess the impact of 
different antithrombotic medications. Further assessment 
of these effects may serve to identify new antithrombotic 
agents which could target thrombus architecture and sta-
bility, by affecting platelet packing density and the density 
of the fibrin meshwork. Already some novel antithrombotic 
strategies that reduce thrombosis in experimental conditions 
appear to also reduce thrombus stability. Such targeted phar-
macotherapy could reduce lasting thrombotic occlusion.
In conclusion, there is substantial evidence from in vitro 
and in vivo studies that many antithrombotic medications 
have shear-dependent effects, potentiating the fragility of 
the growing thrombus and/or enhancing endogenous throm-
bolytic activity, and this likely contributes to their clinical 
effects. The effects of medications on thrombus stability 
should be further assessed in clinical settings and could 
become a new pharmacological target.
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